Newport

By wmadministrator

Newport-based Xanodyne Pharmaceuticals Inc. has sold the global rights of women’s health product Lystedal to Ferring Pharmaceuticals, a privately owned specialty biopharmaceutical group headquartered in Switzerland. The sale is part of Xanodyne’s plan to tighten its focus on the pain management market, where it has a decade-long history with brands such as Darvocet and Roxicodone. The most recent addition to the company’s pain portfolio is Zipsor liquid-filled capsules, a non-steroidal anti-inflammatory drug that was approved by the FDA in June 2009. Financial details of the Xanodyne-Ferring transaction have not been disclosed.

Add Comment

Click here to post a comment

Please wait...

Subscribe to the FASTER LANE business newsletter.

Subscribe and receive breaking Kentucky business news and updates daily.